Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
IPO Year: 2007
Exchange: NASDAQ
Website: masimo.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | $170.00 | Mkt Perform → Outperform | Raymond James |
| 6/3/2024 | $126.00 → $160.00 | Neutral → Overweight | Piper Sandler |
| 4/15/2024 | $148.00 → $170.00 | Hold → Buy | Stifel |
| 3/25/2024 | $117.00 → $160.00 | Equal Weight → Overweight | Wells Fargo |
| 1/30/2024 | $107.00 → $121.00 | Buy → Hold | Jefferies |
| 1/3/2024 | Buy → Hold | Needham | |
| 11/8/2023 | Outperform → Mkt Perform | Raymond James | |
| 7/18/2023 | $205.00 → $120.00 | Buy → Hold | Stifel |
| 7/10/2023 | $173.00 | Equal Weight | Wells Fargo |
| 2/22/2023 | $187.00 | Mkt Perform → Outperform | Raymond James |
8-K - MASIMO CORP (0000937556) (Filer)
8-K - MASIMO CORP (0000937556) (Filer)
10-Q - MASIMO CORP (0000937556) (Filer)
8-K - MASIMO CORP (0000937556) (Filer)
8-K - MASIMO CORP (0000937556) (Filer)
8-K - MASIMO CORP (0000937556) (Filer)
8-K - MASIMO CORP (0000937556) (Filer)
DEFA14A - MASIMO CORP (0000937556) (Filer)
DEFA14A - MASIMO CORP (0000937556) (Filer)
DEFA14A - MASIMO CORP (0000937556) (Filer)
- Reuters Citing CNBC
Highlights Quentin Koffey's Actions That Have Flown in the Face of Good GovernanceMasimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) today highlighted the actions taken by Politan and Quentin Koffey since Masimo's 2023 Annual Meeting of Stockholders that directly contradict their purported commitment to good governance.Over the past twelve months, we believe Politan's Quentin Koffey has repeatedly acted against the best interests of Masimo and its stockholders. The summary provided below shows stockholders and the public the numerous actions Politan has taken to advance its own agenda at the expense of Masimo's governance and stockholder value.
Masimo Corporation (NASDAQ:MASI) shares are trading lower on Tuesday. Yesterday, Masimo reportedly disclosed that a potential joint venture partner is poised to bid between $850 million and $950 million for its consumer business encompassing health and audio products, reported Reuters. Masimo is currently engaged in active discussions with this unnamed partner regarding the joint venture terms, including Masimo’s proposal to manage ongoing litigation outcomes with Apple Inc. (NASDAQ:AAPL). Also Read: Masimo CEO ‘Wholeheartedly’ Feels Apple Watch Users Are Better Off Without Blood Oxygen Monitoring Feature Today, the company disclosed the preliminary results for the second quarter
Needham analyst Mike Matson reiterates Masimo (NASDAQ:MASI) with a Hold.
Masimo Corporation (NASDAQ:MASI) today announced preliminary revenue and select financial results for the second quarter ended June 29, 2024.Preliminary Second Quarter 2024 Revenue and Select Financial Results:Consolidated revenue is expected to be approximately $496 million, representing 9% growth on a reported basis and 10% growth on a constant currency basis;Healthcare revenue is expected to be approximately $344 million, representing 22% growth on a reported basis and 23% growth on a constant currency basis;Non-healthcare revenue is expected to be approximately $152 million, representing a 13% decline on a reported basis and an 11% decline on a constant currency basis;Incremental value o
- Reuters
Sleep Halo Sleep Metrics Are Based on Masimo W1's Continuous Pulse Oximetry Measurements and Advanced Halo AI TechnologyMasimo (NASDAQ:MASI), today announced that the Masimo W1® Sport advanced health tracking wearable is gaining a powerful new feature: scientifically based sleep analysis with Sleep Halo™. Sleep Halo offers overnight sleep data tracking with an unmatched 70,000+ daily measurements of second-by-second continuous health data.
On June 26, 2024, Bilal Muhsin, the Chief Operating Officer of Masimo Corporation (the “Company”) sent a letter (the “Muhsin Conditional Resignation Letter”) to Craig Reynolds, the Lead Independent Director of the Company’s Board of Directors, notifying Mr. Reynolds of Mr. Mushin’s intent to resign as the Company’s Chief Operating Officer in the event that Joe Kiani is removed as the Company’s Chairman of the Board and Chief Executive Officer. Mr. Muhsin’s conditional resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices; however, in the Muhsin Conditional Resignation Letter, Mr. Muhsin noted the following: “I s
Third Quarter 2024 Highlights: Healthcare revenue of $343.3 million increased 11.5% on a reported basis and 11.7% on a constant currency basis(1); GAAP net income per diluted share was $0.18; and Non-GAAP(1) net income per diluted share was $0.98. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Results Consolidated revenue was $504.6 million, comprised of healthcare revenue of $343.3 million and non-healthcare revenue of $161.3 million. Shipments of noninvasive technology boards and instruments were 60,500. GAAP operating income was $30.1 million and non-GAAP(1) operating income was $80.8
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release third quarter 2024 financial results for the period ended September 28, 2024, after the market closes on Tuesday, November 5, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Michelle Brennan, interim Chief Executive Officer, Micah Young, Executive Vice President and Chief Financial Officer and Bilal Muhsin, Chief Operating Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a re
Highlights Risk to Continued Momentum and Innovation if Politan Gains Board Control Urges Stockholders to Vote "FOR" Only Masimo's Director Nominees, Joe Kiani and Christopher Chavez, on the Updated GOLD Proxy Card Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on September 19, 2024, highlighting the Company's commitment to long-term value creation and the risks to its continued momentum and innovation if Politan were to gain control of the Company's Board of Direct
Second Quarter 2024 Highlights: Consolidated revenue was $496.3 million; Healthcare revenue was $343.9 million; Non-healthcare revenue was $152.4 million; GAAP net income per diluted share was $0.29; and Non-GAAP net income per diluted share was $0.86. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the second quarter ended June 29, 2024. Second Quarter 2024 Results: Consolidated revenue was $496.3 million, comprised of healthcare revenue of $343.9 million and non-healthcare revenue of $152.4 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 58,600. Consolidated GAAP
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release second quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, August 6, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the cal
First Quarter 2024 Highlights: Consolidated revenue was $492.8 million; Healthcare revenue was $339.6 million; Non-healthcare revenue was $153.2 million; GAAP net income per diluted share was $0.35; and Non-GAAP net income per diluted share was $0.77. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Results: Consolidated revenue was $492.8 million, comprised of healthcare revenue of $339.6 million and non-healthcare revenue of $153.2 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 50,400. Consolidated GAAP o
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release first quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, May 7, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call wi
Fourth Quarter 2023 Highlights: Consolidated revenue was $548.9 million; Healthcare revenue was $339.9 million; Non-healthcare revenue was $209.0 million; GAAP net income per diluted share of $0.63; and Non-GAAP net income per diluted share (updated definition) of $1.25. Full-Year 2023 Highlights: Consolidated revenue was $2,048.1 million; Healthcare revenue was $1,275.5 million; Non-healthcare revenue was $772.6 million. GAAP net income per diluted share of $1.51; and Non-GAAP net income per diluted share (updated definition) of $3.79. Masimo (NASDAQ:MASI) today announced its financial results for the fourth quarter and full-year ended December 30, 2023.
Complete fourth quarter and full-year 2023 financial results will be announced on Tuesday, February 27, 2024 Masimo Corporation (NASDAQ:MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 30, 2023 and provided estimates for its full-year 2024 guidance. Preliminary Fourth Quarter 2023 Financial Results: • Consolidated revenue of $541 million to $551 million; • Healthcare revenue of $336 million to $341 million; and • Non-healthcare revenue of $205 million to $210 million. Preliminary Full-Year 2023 Financial Results: •
Third Quarter 2023 Highlights Consolidated revenue was $478.9 million; Healthcare revenue was $307.8 million; Non-healthcare revenue was $171.1 million; GAAP net income per diluted share was $0.20; and Non-GAAP net income per diluted share was $0.63. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter 2023 Financial Results Consolidated revenue was $478.9 million, comprised of healthcare revenue of $307.8 million and non-healthcare revenue of $171.1 million. Shipments of noninvasive technology boards and instruments were 63,100. Consolidated GAAP operating income was $25.2 mi
Masimo (NASDAQ:MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers &
Masimo (NASDAQ:MASI) today announced that its management will participate in the Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 11:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bower
Third Quarter 2024 Highlights: Healthcare revenue of $343.3 million increased 11.5% on a reported basis and 11.7% on a constant currency basis(1); GAAP net income per diluted share was $0.18; and Non-GAAP(1) net income per diluted share was $0.98. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Results Consolidated revenue was $504.6 million, comprised of healthcare revenue of $343.3 million and non-healthcare revenue of $161.3 million. Shipments of noninvasive technology boards and instruments were 60,500. GAAP operating income was $30.1 million and non-GAAP(1) operating income was $80.8
Renowned Healthcare Facility Launches Advanced Wireless Monitoring Technology in the Emergency Department, Reducing Wait Times and Improving Patient Prioritization Masimo (NASDAQ:MASI) today announced that Vanderbilt University Medical Center (VUMC), a renowned healthcare facility in Nashville, Tennessee, is piloting the use of the Masimo Radius VSM™ patient-worn vital signs monitor with Masimo Patient SafetyNet™ supplemental remote monitoring in the Emergency Department (ED) and nontraditional care spaces. Launched as part of a successful pilot program aimed at tackling the ongoing crisis of emergency room congestion, Radius VSM has been used on hallway beds, in the emergency medical serv
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release third quarter 2024 financial results for the period ended September 28, 2024, after the market closes on Tuesday, November 5, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Michelle Brennan, interim Chief Executive Officer, Micah Young, Executive Vice President and Chief Financial Officer and Bilal Muhsin, Chief Operating Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a re
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
Appoints Michelle Brennan as Interim CEO Following Joe Kiani's Decision to Resign Continues to Be Committed to Review of Strategic Alternatives for Consumer Businesses, With Assistance From Leading Financial and Legal Advisors Reaffirms Financial Guidance for Third Quarter 2024 Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI) a leading global medical innovator, provided a series of leadership and business updates: Leadership Appointments Michelle Brennan, a current member of Masimo's Board, has been appointed interim Chief Executive Officer ("CEO") following Chairman and CEO Joe Kiani informing the Board of his decision to resign as CEO. After being elected by shareho
Politan Capital Management (together with its affiliates, "Politan"), a 9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today commented on the outcome of the Company's Annual Meeting of Stockholders (the "Annual Meeting"). Both of Politan's independent nominees – Darlene Solomon and William Jellison – were elected to the Board.1 Politan greatly appreciates the support and engagement from its fellow Masimo shareholders during this process. Darlene Solomon, William Jellison, Michelle Brennan and Quentin Koffey issued the following joint statement: "While each of us is independent and brings our own unique perspectives, we are united in our enthusiasm for
Glass Lewis States That Politan's Nominees Represent a "Clear, Reasoned and Compelling Alternative to the Status Quo" Believes Investors Should Have "Little Confidence" in Existing Board's Ability to Advance Review of Strategic Alternatives Stresses that Politan's Nominees "Would Go a Long Way to Ensuring the Interests of All Investors Are Clearly and Consistently Represented" Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today highlighted that leading proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") has updated its earlier report to reiterate its recommendation that shareho
Details How Independent Third Parties and the Evidence in Legal Proceedings Have Consistently Refuted Masimo's "Defensive Rhetoric" and How Company's Attacks on Politan Continue to "Crumble Under Basic Scrutiny" Shareholders Can Vote for Politan's Independent Nominees, Darlene Solomon and William Jellison, on the WHITE Card and Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today issued an open letter to shareholders in advance of the Company's 2024 Annual Meeting of Stockholders (the "Annual Meeting"), set for September 19. Th
Raymond James upgraded Masimo from Mkt Perform to Outperform and set a new price target of $170.00
Piper Sandler upgraded Masimo from Neutral to Overweight and set a new price target of $160.00 from $126.00 previously
Stifel upgraded Masimo from Hold to Buy and set a new price target of $170.00 from $148.00 previously
Wells Fargo upgraded Masimo from Equal Weight to Overweight and set a new price target of $160.00 from $117.00 previously
Jefferies downgraded Masimo from Buy to Hold and set a new price target of $121.00 from $107.00 previously
Needham downgraded Masimo from Buy to Hold
Raymond James downgraded Masimo from Outperform to Mkt Perform
Stifel downgraded Masimo from Buy to Hold and set a new price target of $120.00 from $205.00 previously
Wells Fargo initiated coverage of Masimo with a rating of Equal Weight and set a new price target of $173.00
Raymond James upgraded Masimo from Mkt Perform to Outperform and set a new price target of $187.00
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13G/A - MASIMO CORP (0000937556) (Subject)
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
3 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
3 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
3 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
Appoints Michelle Brennan as Interim CEO Following Joe Kiani's Decision to Resign Continues to Be Committed to Review of Strategic Alternatives for Consumer Businesses, With Assistance From Leading Financial and Legal Advisors Reaffirms Financial Guidance for Third Quarter 2024 Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI) a leading global medical innovator, provided a series of leadership and business updates: Leadership Appointments Michelle Brennan, a current member of Masimo's Board, has been appointed interim Chief Executive Officer ("CEO") following Chairman and CEO Joe Kiani informing the Board of his decision to resign as CEO. After being elected by shareho
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Bob Chapek Joins Masimo's Board of Directors Masimo (NASDAQ:MASI) announced today that Bob Chapek has been appointed to Masimo's Board of Directors. Mr. Chapek was Chief Executive Officer of The Walt Disney Company, one of the world's largest media and entertainment companies, from February 2020 to November 2022, successfully leading Disney through the global COVID-19 pandemic and recovery. Under his leadership, Disney strategically realigned its media and entertainment divisions, expanded the scale and global reach of its streaming services, made transformative changes to its parks and resorts worldwide, and leveraged new and innovative technologies to bring stories to life in more immer
Rolf A. Classon Joins Masimo's Board of Directors Masimo (NASDAQ:MASI) announced today that Rolf A. Classon has been appointed to Masimo's Board of Directors. Mr. Classon is an experienced medical technology executive and board member. From October 2002 until his retirement in July 2004, he was Chairman of the Executive Committee of Bayer HealthCare AG. He served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President of Bayer Diagnostics from 1991 to 1995. Prior to 1991, Mr. Classon held various management positions with Pharmacia Corporation. Mr. Classon has served as Vice Chairman of the Supervisory Board of Fresenius Medical Care AG & Co. KGaA since 2011,
Vote the WHITE Proxy Card Today Visit KeepMasimoStrong.com for More Information The Board of Directors of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) today issued a letter to stockholders in connection with the Company's Annual Meeting of Stockholders to be held on June 26, 2023. To protect stockholders' investment and to ensure Masimo continues to innovate breakthrough solutions to help improve lives, improve patient outcomes and reduce cost of care, and take noninvasive monitoring to new sites and applications, the Board encourages stockholders to vote FOR Masimo's highly qualified director nominees, H Michael Cohen and Julie Shimer, Ph.D. Your vote on the WHITE pro
Mr. Kiani Previously Waived Other Rights in Connection with the 2023 Annual Meeting of Stockholders and the Appointment of a Lead Independent Director Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) today announced that Joe Kiani, founder, Chairman and Chief Executive Officer of Masimo, unconditionally, irrevocably and permanently waived his right to assert that a Change in Control has occurred pursuant to Section 9(iii) of his employment agreement unless there occurs a change in the Company's Board in which the individuals who constituted the Board at the beginning of the twelve (12) month period immediately preceding the change cease for any reason to constitute one-half or
Commitment to Appoint Politan Nominee as Director Reflects Board's Openness to Qualified and Experienced Perspectives Stockholders Do Not Need to Vote for Ms. Brennan to Add Her to Board Board Strongly Encourages Stockholders to Protect Their Investment by Voting FOR H Michael Cohen and Julie Shimer, Ph.D., and FOR Board Expansion on the WHITE Proxy Card The Board of Directors of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) today announced its commitment to appoint Michelle Brennan as the Company's sixth director, pending stockholder approval of the proposal to expand the Board of Directors to seven and the election of the Company's highly qualified director nominees,
Responds and Corrects Politan's Inaccurate Letter Highlights Politan's Reckless Disregard for the Truth and Fundamental Misunderstanding of Masimo's Business Strongly Encourages Stockholders to Protect Their Investment by Voting FOR H Michael Cohen and Julie Shimer, Ph.D., on the WHITE Proxy Card The Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) Board of Directors today issued a letter to stockholders to set the record straight on the many highly misleading and inaccurate claims recently published by Politan Capital Management ("Politan"). Politan's reckless and unprincipled willingness to distort the truth in pursuit of its agenda shows its founder and nominee Quentin
H Michael Cohen Selected as Lead Independent Director Two Additional New Directors to Be Named to Board Following Consultation with Stockholders Significant Governance Changes Announced, Including Termination of Rights Agreement and Plan to Declassify Board Masimo Corporation (NASDAQ:MASI) today announced changes to its Board of Directors and governance policies, the result of an ongoing board refreshment and governance review process informed by regular engagement with stockholders. "We recently visited several of our large stockholders and had good discussions with them," said Joe Kiani, Masimo's founder, Chairman, and CEO. "Based on their feedback, as well as feedback we previously r